Advertisement
Table 1 Baseline characteristics of the 101 patients with bone marrow metastatic neuroblastoma
| Characteristic | Total [cases (%)] |
|---|---|
| Age (months) | |
| < 18 | 16 (15.8) |
| ≥ 18 | 85 (84.2) |
| Sex | |
| Male | 57 (56.4) |
| Female | 44 (43.6) |
| WBC (× 109/L) | |
| > 10 | 17 (16.8) |
| 4–10 | 60 (59.4) |
| < 4 | 24 (23.8) |
| Hemoglobin (g/L) | |
| > 120 | 8 (7.9) |
| 90–120 | 59 (58.4) |
| 60–89 | 33 (32.7) |
| < 60 | 1 (1.0) |
| Platelet (× 109/L) | |
| > 300 | 47 (46.5) |
| 100–300 | 48 (47.5) |
| < 100 | 6 (6.0) |
| Risk stratification | |
| Low-risk | 1 (1.0) |
| Intermediate-risk | 7 (6.9) |
| High-risk | 93 (92.1) |
| Primary tumor site | |
| Abdomen | 88 (87.1) |
| Thorax | 12 (11.9) |
| Neck | 1 (1.0) |
| 11q23 deletion | |
| Yes | 40 (39.6) |
| No | 61 (60.4) |
| MYCN amplification | |
| Yes | 12 (11.9) |
| No | 89 (88.1) |
| LDH (IU/L) | |
| < 1500 | 79 (78.2) |
| ≥ 1500 | 22 (21.8) |
| NSE (ng/mL) | |
| < 370 | 60 (59.4) |
| ≥ 370 | 41 (40.6) |
| Event | |
| No event | 49 (48.5) |
| Relapse/progression | 13 (12.9) |
| Death | 39 (38.6) |
